These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29317712)

  • 1. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
    Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
    Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
    Ordóñez NG; Sahin AA
    Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
    Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
    Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
    Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
    Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
    Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
    Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
    Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
    Naso JR; Churg A
    Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
    Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma.
    Llinares K; Escande F; Aubert S; Buisine MP; de Bolos C; Batra SK; Gosselin B; Aubert JP; Porchet N; Copin MC
    Mod Pathol; 2004 Feb; 17(2):150-7. PubMed ID: 14657954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.